{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:04Z","timestamp":1794047464956,"version":"4.8.0"},"reference-count":31,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"10","license":[{"start":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T00:00:00Z","timestamp":1709769600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Follicular lymphoma (FL) treatment initiation is largely determined by tumor burden and symptoms. In the pre-rituximab era, the Group d\u2019Etude des Lymphomes Folliculaires (GELF) developed widely adopted criteria to identify high tumor burden FL patients to harmonize clinical trial populations. The utilization of GELF criteria (GELFc) in routine therapeutic decision- making is poorly described. This multicenter retrospective study evaluated patterns of GELFc at presentation and GELFc utilization in therapeutic decision-making in newly diagnosed, advanced-stage rituximab-era FL. Associations between GELFc, treatment given, and patient survival were analyzed in 300 eligible cases identified between 2002-2019. One hundred and sixty-three (54%) had \u22651 GELFc at diagnosis. The presence or cumulative number of GELFc did not predict progression-free survival in patients undergoing watch-and-wait (W&amp;W) or those receiving systemic treatment. Of interest, in patients with \u22651 GELFc, 16 of 163 (10%) underwent initial W&amp;W (comprising 22% of the W&amp;W cohort). In those receiving systemic therapy +\/- radiotherapy, 74 of 215 (34%) met no GELFc. Our data suggest clinicians are using adjunctive measures to make decisions regarding treatment initiation in a significant proportion of patients. By restricting FL clinical trial eligibility only to those meeting GELFc, reported outcomes may not be applicable to a significant proportion of patients treated in routine care settings.<\/jats:p>","DOI":"10.3324\/haematol.2023.284538","type":"journal-article","created":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T02:10:55Z","timestamp":1709777455000},"page":"3338-3345","source":"Crossref","is-referenced-by-count":16,"title":["Impact and utility of follicular lymphoma GELF criteria in routine care: an Australasian Lymphoma Alliance study"],"prefix":"10.3324","volume":"109","author":[{"given":"Allison","family":"Barraclough","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivam","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipti","family":"Talaulikar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chan Y.","family":"Cheah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nunzio","family":"Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Mutsando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Tahir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Trotman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colm","family":"Keane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchel","family":"Lincoln","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Cochrane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna M.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Dickinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Opat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe K.","family":"McQuilten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica M.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gayathri","family":"St George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliza A.","family":"Hawkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,3,7]]},"reference":[{"key":"67447","doi-asserted-by":"crossref","unstructured":"Tan D, Horning SJ, Hoppe RT. Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience. Blood. 2013; 122(6):981-987.","DOI":"10.1182\/blood-2013-03-491514"},{"key":"67448","unstructured":"Swerdlow SH CE HN, Jafie ES. World Health Organization classification of tumors of haematopoietic and lymphoid tissues. Lyon France. IARC Press. 2017."},{"key":"67449","doi-asserted-by":"crossref","unstructured":"Johnson PW, Rohatiner AZ, Whelan JS. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol. 1995; 13(1):140-147.","DOI":"10.1200\/JCO.1995.13.1.140"},{"key":"67450","doi-asserted-by":"crossref","unstructured":"Magnano L, Alonso-Alvarez S, Alcoceba M. Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population. Br J Haematol. 2019; 185(3):480-491.","DOI":"10.1111\/bjh.15805"},{"key":"67451","doi-asserted-by":"crossref","unstructured":"Batlevi CL, Sha F, Alperovich A. Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups. Blood Cancer J. 2020; 10(7):74.","DOI":"10.1038\/s41408-020-00340-z"},{"key":"67452","doi-asserted-by":"crossref","unstructured":"Portlock CS, Rosenberg M. No initial therapy for stage III and IV non-Hodgkin\u2019s lymphomas of favorable histologic types. Ann Intern Med. 1979; 90(1):10-13.","DOI":"10.7326\/0003-4819-90-1-10"},{"key":"67453","unstructured":"Young RC, Longo DL, Glatstein E, Ihde DC, Jaffe ES, DeVita VT. The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. Semin Hematol. 1988; 25(2 Suppl 2):11-16."},{"key":"67454","doi-asserted-by":"crossref","unstructured":"Ardeshna KM, Smith P, Norton A. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet. 2003; 362(9383):516-522.","DOI":"10.1016\/S0140-6736(03)14110-4"},{"key":"67455","doi-asserted-by":"crossref","unstructured":"Ardeshna KM, Qian W, Smith P. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. Lancet Oncol. 2014; 15(4):424-435.","DOI":"10.1016\/S1470-2045(14)70027-0"},{"key":"67456","doi-asserted-by":"crossref","unstructured":"Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin\u2019s lymphomas. N Engl J Med. 1984; 311(23):1471-1475.","DOI":"10.1056\/NEJM198412063112303"},{"key":"67457","doi-asserted-by":"crossref","unstructured":"Wilder RB, Jones D, Tucker SL. Long-term results with radiotherapy for Stage I-II follicular lymphomas. Int J Radiat Oncol Biol Phys. 2001; 51(5):1219-1227.","DOI":"10.1016\/S0360-3016(01)01747-3"},{"key":"67458","doi-asserted-by":"crossref","unstructured":"Mac Manus MP, Hoppe RT. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol. 1996; 14(4):1282-1290.","DOI":"10.1200\/JCO.1996.14.4.1282"},{"key":"67459","doi-asserted-by":"crossref","unstructured":"Brady JL, Binkley MS, Hajj C. Definitive radiotherapy for localized follicular lymphoma staged by (18)F-FDG PET-CT: a collaborative study by ILROG. Blood. 2019; 133(3):237-245.","DOI":"10.1182\/blood-2018-04-843540"},{"key":"67460","doi-asserted-by":"crossref","unstructured":"MacManus M, Fisher R, Roos D. Randomized trial of systemic therapy after involved-field radiotherapy in patients with early-stage follicular lymphoma: TROG 99.03. J Clin Oncol. 2018; 36(29):2918-2925.","DOI":"10.1200\/JCO.2018.77.9892"},{"key":"67461","doi-asserted-by":"crossref","unstructured":"Friedberg JW, Byrtek M, Link BK. Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study. J Clin Oncol. 2012; 30(27):3368-3375.","DOI":"10.1200\/JCO.2011.40.6546"},{"key":"67462","doi-asserted-by":"crossref","unstructured":"Brice P, Bastion Y, Lepage E. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d\u2019Etude des Lymphomes Folliculaires. Groupe d\u2019Etude des Lymphomes de l\u2019Adulte. J Clin Oncol. 1997; 15(3):1110-1117.","DOI":"10.1200\/JCO.1997.15.3.1110"},{"key":"67463","doi-asserted-by":"crossref","unstructured":"Morschhauser F, Fowler NH, Feugier P. Rituximab plus lenalidomide in advanced untreated follicular lymphoma. N Engl J Med. 2018; 379(10):934-947.","DOI":"10.1056\/NEJMoa1805104"},{"key":"67464","doi-asserted-by":"crossref","unstructured":"Marcus R, Davies A, Ando K. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med. 2017; 377(14):1331-1344.","DOI":"10.1056\/NEJMoa1614598"},{"key":"67465","unstructured":"NCCN. B-Cell Lymphomas. National Comprehensive Cancer Network clinical practice guidelines in oncology. 2022. Publisher Full Text|"},{"key":"67466","doi-asserted-by":"crossref","unstructured":"Dreyling M, Ghielmini M, Rule S. Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021; 32(3):298-308.","DOI":"10.1016\/j.annonc.2020.11.008"},{"key":"67467","doi-asserted-by":"crossref","unstructured":"Bennett MH F-BG, Henry K, Jelliffe AM. Classification of non-Hodgkins lymphomas. Lancet. 1974; 2:405-406.","DOI":"10.1016\/S0140-6736(74)91786-3"},{"key":"67468","doi-asserted-by":"crossref","unstructured":"Solal-C\u00e9ligny P, Lepage E, Brousse N. Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d\u2019Etude des Lymphomes Folliculaires 86 Trial. J Clin Oncol. 1998; 16(7):2332-2338.","DOI":"10.1200\/JCO.1998.16.7.2332"},{"key":"67469","doi-asserted-by":"crossref","unstructured":"Lymphoma Related Diseases Registry I. Improving outcomes for patients with lymphoma: design and development of the Australian and New Zealand Lymphoma and Related Diseases Registry. BMC Med Res Methodol. 2022; 22(1):266.","DOI":"10.1186\/s12874-022-01728-0"},{"key":"67470","doi-asserted-by":"crossref","unstructured":"Bland JM, Altman DG. Survival probabilities (the Kaplan-Meier method). BMJ. 1998; 317(7172):1572.","DOI":"10.1136\/bmj.317.7172.1572"},{"key":"67471","doi-asserted-by":"crossref","unstructured":"Khurana A, Mwangi R, Ansell SM. Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab era. Blood Cancer J. 2021; 11(7):133.","DOI":"10.1038\/s41408-021-00525-0"},{"key":"67472","doi-asserted-by":"crossref","unstructured":"Epperla N, Pham AQ, Burnette BL. Risk of histological transformation and therapy-related myelodysplasia\/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphoma. Br J Haematol. 2017; 178(3):427-433.","DOI":"10.1111\/bjh.14688"},{"key":"67473","doi-asserted-by":"crossref","unstructured":"Wagner LI, Zhao F, Hong F. Anxiety and health-related quality of life among patients with low-tumor burden non-Hodgkin lymphoma randomly assigned to two different rituximab dosing regimens: results from ECOG trial E4402 (RESORT). J Clin Oncol. 2015; 33(7):740-748.","DOI":"10.1200\/JCO.2014.57.6801"},{"key":"67474","doi-asserted-by":"crossref","unstructured":"Casulo C, Dixon JG, Le-Rademacher J. Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials. Blood. 2022; 139(11):1684-1693.","DOI":"10.1182\/blood.2020010263"},{"key":"67475","doi-asserted-by":"crossref","unstructured":"Pastore A, Jurinovic V, Kridel R. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol. 2015; 16(9):1111-1122.","DOI":"10.1016\/S1470-2045(15)00169-2"},{"key":"67476","doi-asserted-by":"crossref","unstructured":"Hawkes EA, Manos K, Khor R. Frontline treatment of follicular lymphoma with atezolizumab and obinutuzumab, with and without radiotherapy (The FLUORO study). J Clin Oncol. 2022; 40(Suppl 16):TPS7587.","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS7587"},{"key":"67477","doi-asserted-by":"crossref","unstructured":"Barraclough A, Chong G, Gilbertson M. Immune priming with single-agent nivolumab followed by combined nivolumab &amp; amp; rituximab is safe and efficacious for first-line treatment of follicular lymphoma; interim analysis of the \u20181st FLOR\u2019 Study. Blood. 2019; 134(Suppl 1):1523.","DOI":"10.1182\/blood-2019-123908"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284538\/76731","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284538\/77578","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11497\/76731","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:05:57Z","timestamp":1794045957000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.284538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,7]]},"references-count":31,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,10,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.284538","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,7]]}}}